We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ReNeuron Scientists Generate Pancreatic Cell Lines for Treatment of Diabetes
News

ReNeuron Scientists Generate Pancreatic Cell Lines for Treatment of Diabetes

ReNeuron Scientists Generate Pancreatic Cell Lines for Treatment of Diabetes
News

ReNeuron Scientists Generate Pancreatic Cell Lines for Treatment of Diabetes

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ReNeuron Scientists Generate Pancreatic Cell Lines for Treatment of Diabetes"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ReNeuron Group plc has announced that it has taken a major step forward with its ReN002 diabetes programme with the generation of new data concerning its pancreatic cell lines for the treatment of Type 1 (juvenile) diabetes.

ReNeuron scientists have generated stable human pancreatic cell lines that form islet-like cell clusters. These clusters were shown to secrete insulin in response to glucose concentrations, demonstrating their potential as a cell therapy candidate for Type 1, insulin-dependent, diabetes patients.

The cell lines were generated using ReNeuron's patented c-mycER stem cell expansion technology, and can be continuously grown in culture. The cell lines were pre-screened for both genetic stability and their ability to express the appropriate phenotypic markers for insulin-producing beta cells, such as the islet cell transcription factor PDX1 and the functional beta cell receptor GLP1R.

These results will be presented at the JDRF Center for Beta Cell Therapy in Diabetes' 2007 Training Course in Bath, UK on 26-28 June. The ReN002 cells are currently being taken forward into pre-clinical models of diabetes.

The Company believes that its ability to efficiently expand well-characterised ReN002 cells using its c-mycER technology may offer a solution to the current problem facing experimental islet cell transplantation – the limited availability of donated pancreas tissue from which to derive purified islets.

Commenting on the announcement, Dr John Sinden, Chief Scientific Officer of ReNeuron, said: "We are excited by these results with our ReN002 programme, not least because having already demonstrated the ability of our c-mycER stem cell expansion platform to generate viable cell lines for neurological disorders, these new data indicate the potential of the technology to work in other significant disease areas. We now have the basis of a scalable cell therapy approach to Type 1 diabetes, a major disease target and one in which we believe cell therapy will play an important role in addressing in the future."

Advertisement